LithiumBank Resources

BioTech Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 821.67
10.17 1.25
827,238
107.08M
US$ 87.980B
US$ 153.58
6.14 4.16
3.45M
384.18M
US$ 59.000B
US$ 124.57
2.00 1.63
803,619
242.68M
US$ 30.230B
US$ 7.38
0.07 0.96
2.75M
725.42M
US$ 5.350B
US$ 24.11
0.31 1.30
747,349
159.67M
US$ 3.850B
US$ 16.58
-0.57 -3.32
2.58M
149.48M
US$ 2.480B
US$ 7.54
0.12 1.62
1.33M
286.10M
US$ 2.160B
US$ 80.06
0.71 0.89
338,084
25.75M
US$ 2.060B
US$ 1.33
0.10 8.13
19.09M
1.47B
US$ 1.960B
US$ 29.34
1.63 5.88
1.47M
66.26M
US$ 1.940B
US$ 29.63
1.36 4.81
846,637
54.86M
US$ 1.630B
US$ 30.81
0.28 0.92
512,724
43.85M
US$ 1.350B
US$ 26.09
0.67 2.64
282,320
51.01M
US$ 1.330B
US$ 6.67
0.22 3.41
1.08M
181.70M
US$ 1.210B
US$ 24.12
0.11 0.46
924,758
41.74M
US$ 1.010B
US$ 1.94
0.11 6.01
2.01M
488.43M
US$ 947.550M
US$ 31.01
-0.94 -2.94
1.84M
29.40M
US$ 911.690M
US$ 7.27
-1.56 -17.67
348,597
125.28M
US$ 910.790M
US$ 18.40
0.22 1.21
442,387
46.30M
US$ 851.920M
US$ 29.90
0.40 1.36
719
24.87M
US$ 743.610M
US$ 11.32
-0.06 -0.53
345,251
61.54M
US$ 696.630M
US$ 8.57
0.25 3.00
1.38M
78.03M
US$ 668.720M
US$ 21.27
-0.50 -2.30
130,770
29.69M
US$ 631.510M
US$ 3.27
0.16 5.14
1.03M
190.73M
US$ 623.690M
US$ 11.84
0.09 0.77
1.18M
49.52M
US$ 586.320M
US$ 8.51
-0.24 -2.74
4,320
67.39M
US$ 573.490M
US$ 16.53
0.33 2.04
61,435
33.35M
US$ 551.280M
US$ 8.09
-0.24 -2.88
664,128
66.68M
US$ 539.440M
US$ 0.63
0.03 4.17
2.01M
851.56M
US$ 532.220M
US$ 1.36
0.00 0.00
1.93M
363.49M
US$ 494.350M
US$ 2.43
0.10 4.29
591,106
188.73M
US$ 458.610M
US$ 9.93
-0.45 -4.34
285,483
42.58M
US$ 422.820M
US$ 6.67
0.01 0.15
430,662
63.26M
US$ 421.940M
US$ 4.09
-0.35 -7.88
61,275
91.20M
US$ 373.010M
US$ 3.85
-0.05 -1.28
155,113
94.60M
US$ 364.210M
US$ 1.66
0.01 0.61
1.13M
217.39M
US$ 360.870M
US$ 5.38
0.14 2.67
132,755
65.65M
US$ 353.200M
US$ 25.88
-0.40 -1.52
378
13.01M
US$ 336.700M
US$ 1.11
0.05 4.72
4.31M
296.92M
US$ 329.580M
US$ 5.77
0.07 1.23
195,641
55.94M
US$ 322.770M
US$ 3.09
0.18 6.19
165,118
103.12M
US$ 318.640M
US$ 6.03
-0.09 -1.47
79,831
48.05M
US$ 289.740M
US$ 12.23
0.35 2.95
213,430
23.63M
US$ 288.990M
US$ 9.71
-0.25 -2.51
43,019
26.40M
US$ 256.340M
US$ 5.80
0.18 3.20
768,376
39.90M
US$ 231.420M
US$ 8.74
-0.03 -0.34
76,486
25.70M
US$ 224.620M
US$ 5.71
0.12 2.15
42,079
37.84M
US$ 216.070M
US$ 7.76
0.32 4.30
387,493
27.66M
US$ 214.640M
US$ 0.21
-0.0025 -1.17
2.84M
979.95M
US$ 207.460M
US$ 13.11
0.68 5.47
22,428
14.64M
US$ 191.930M
US$ 2.85
0.17 6.34
211,600
63.99M
US$ 182.370M
US$ 7.24
0.13 1.83
176,966
24.40M
US$ 176.660M
US$ 3.55
0.15 4.41
808,969
48.81M
US$ 173.280M
US$ 1.75
0.07 4.17
266,792
92.39M
US$ 161.680M
US$ 5.98
0.28 4.91
51,896
24.53M
US$ 146.690M
US$ 2.45
0.04 1.66
54,280
58.16M
US$ 142.490M
US$ 2.21
0.09 4.26
7,963
60.94M
US$ 134.370M
US$ 1.20
0.02 1.27
485,586
108.98M
US$ 130.780M
US$ 5.16
0.09 1.78
14,368
24.72M
US$ 127.560M
US$ 15.41
-4.69 -23.33
501,081
8.16M
US$ 125.750M
US$ 3.45
-0.16 -4.43
40,665
36.26M
US$ 125.100M
US$ 2.10
-0.07 -3.23
45,247
59.43M
US$ 124.800M
US$ 1.59
-0.08 -4.79
2.57M
74.60M
US$ 118.610M
US$ 7.45
0.28 3.91
158,997
15.52M
US$ 115.620M
US$ 1.53
0.02 1.32
136,937
74.47M
US$ 113.940M
US$ 2.56
0.00 0.00
0
37.85M
US$ 96.900M
US$ 4.30
-0.60 -12.24
16,783
20.40M
US$ 87.720M
US$ 1.21
0.05 4.31
202,425
71.40M
US$ 86.390M
US$ 1.83
-0.36 -16.44
137,620
43.68M
US$ 79.930M
US$ 2.53
0.00 0.00
0
30.40M
US$ 76.910M
US$ 1.88
0.09 5.03
462,900
40.33M
US$ 75.820M
US$ 3.02
0.25 9.03
14,538
24.96M
US$ 75.380M
US$ 2.90
0.04 1.40
5,051
25.63M
US$ 74.330M
US$ 0.69
-0.0008 -0.12
303,125
107.17M
US$ 74.080M
US$ 4.86
4.29 758.81
187,571
15.03M
US$ 73.050M
US$ 2.77
-0.05 -1.77
21,512
24.94M
US$ 69.080M
US$ 0.81
0.02 2.25
30,181
81.48M
US$ 65.820M
US$ 0.43
-0.0059 -1.35
571,005
151.55M
US$ 65.530M
US$ 1.45
0.00 0.00
8,167
43.42M
US$ 62.960M
US$ 1.55
-0.06 -3.73
42,755
38.50M
US$ 59.680M
US$ 4.82
0.11 2.34
36,509
11.88M
US$ 57.260M
US$ 1.56
0.02 1.30
315,631
36.13M
US$ 56.360M
US$ 4.01
0.15 3.89
4,835
13.59M
US$ 54.500M
US$ 3.09
0.09 3.00
25,246
17.07M
US$ 52.750M
US$ 1.39
-13.90 -90.91
371,958
37.66M
US$ 52.350M
US$ 1.18
0.02 1.72
36,075
43.86M
US$ 51.750M
US$ 1.99
0.01 0.51
15,453
25.67M
US$ 51.080M
US$ 1.78
-0.005 -0.28
22,678
28.56M
US$ 50.840M
US$ 1.50
0.11 7.91
20,178
30.72M
US$ 46.080M
US$ 0.63
0.02 3.21
199,246
69.64M
US$ 43.850M
US$ 1.66
-0.01 -0.60
68,242
26.29M
US$ 43.640M
US$ 1.23
0.03 2.32
13,180
35.17M
US$ 43.360M
US$ 4.73
-0.02 -0.42
2,427
8.58M
US$ 40.580M
US$ 1.02
0.03 3.03
36,043
39.07M
US$ 39.850M
US$ 0.37
-0.02 -4.28
370,807
106.46M
US$ 39.030M
US$ 0.74
0.02 2.18
160,291
52.32M
US$ 38.510M
US$ 3.91
0.13 3.44
102,769
9.51M
US$ 37.180M
US$ 0.59
-0.02 -3.89
791,983
57.54M
US$ 34.010M
US$ 1.40
0.17 13.36
53,488
23.74M
US$ 33.240M
US$ 1.30
0.00 0.00
23,502
24.50M
US$ 31.850M
US$ 3.49
0.12 3.41
49,819
9.10M
US$ 31.710M
US$ 0.49
0.0024 0.49
43,003
63.70M
US$ 31.040M
US$ 0.03
-0.0008 -2.68
131,785
1.01B
US$ 29.290M
US$ 0.33
-0.04 -11.79
3,200
78.85M
US$ 26.370M
US$ 2.77
0.10 3.75
178,293
9.25M
US$ 25.620M
US$ 3.25
0.07 2.04
20,926
7.86M
US$ 25.510M
US$ 1.82
0.10 5.81
30,123
13.93M
US$ 25.350M
US$ 1.86
-0.15 -7.46
55,503
12.70M
US$ 23.620M
US$ 1.91
-0.22 -10.33
687,387
12.04M
US$ 23.000M
US$ 1.19
0.05 4.40
2,350
19.17M
US$ 22.860M
US$ 0.87
-0.0004 -0.05
34,919
25.66M
US$ 22.440M
US$ 0.18
0.0069 3.97
1.06M
110.93M
US$ 20.050M
US$ 0.90
-0.02 -2.27
4,296
22.27M
US$ 20.020M
US$ 0.39
0.05 15.35
86,955
48.14M
US$ 18.920M
US$ 0.45
0.00 0.00
0
40.60M
US$ 18.360M
US$ 1.59
0.04 2.58
20,840
11.53M
US$ 18.330M
US$ 0.91
-0.01 -1.18
95,393
20.06M
US$ 18.300M
US$ 0.28
0.00 0.00
0
64.24M
US$ 18.220M
US$ 1.33
0.08 6.40
43,565
13.53M
US$ 17.990M
US$ 0.29
-0.0006 -0.21
301,621
61.51M
US$ 17.840M
US$ 0.05
-0.0005 -1.04
73,450
369.70M
US$ 17.560M
US$ 0.58
0.04 7.43
121,636
30.11M
US$ 17.460M
US$ 3.40
0.00 0.00
1,040
5.13M
US$ 17.440M
US$ 0.14
0.0095 7.09
1.21M
119.08M
US$ 17.090M
US$ 0.73
0.0028 0.38
167,781
22.59M
US$ 16.510M
US$ 2.72
0.03 0.93
4,777
5.95M
US$ 16.180M
US$ 2.67
0.01 0.38
13,520
6.06M
US$ 16.180M
US$ 1.89
0.09 5.00
12,051
8.37M
US$ 15.820M
US$ 0.05
-0.0032 -6.18
31,956
318.30M
US$ 15.470M
US$ 0.35
0.0029 0.83
109,590
42.40M
US$ 14.950M
US$ 0.21
0.05 33.06
53,523
65.06M
US$ 13.590M
US$ 1.77
0.0025 0.14
178
7.63M
US$ 13.510M
US$ 0.04
-0.0013 -3.15
276,343
317.06M
US$ 12.680M
US$ 0.58
-0.0054 -0.92
9,464
21.75M
US$ 12.660M
US$ 0.05
0.0009 1.83
31,510
239.53M
US$ 12.000M
US$ 0.30
0.02 6.43
186,727
40.25M
US$ 11.990M
US$ 0.39
0.01 3.73
110,408
29.25M
US$ 11.380M
US$ 0.70
0.02 2.69
22,895
15.84M
US$ 11.060M
US$ 0.17
0.00 0.00
0
61.02M
US$ 10.070M
US$ 0.38
-0.01 -2.59
74,086
26.08M
US$ 9.910M
US$ 1.24
-0.03 -2.36
55,189
7.43M
US$ 9.210M
US$ 0.22
0.00 0.00
0
41.99M
US$ 9.080M
US$ 0.70
0.01 1.64
136,740
12.83M
US$ 8.920M
US$ 0.09
0.0075 9.09
60,001
96.89M
US$ 8.720M
US$ 1.43
0.00 0.00
26,907
5.80M
US$ 8.290M
US$ 2.24
0.04 1.81
36,547
3.40M
US$ 7.620M
US$ 1.44
-0.15 -9.43
255,377
5.12M
US$ 7.370M
US$ 3.52
0.87 32.83
40.13M
2.02M
US$ 7.110M
US$ 0.50
0.02 3.18
136,641
14.08M
US$ 7.040M
US$ 0.37
0.02 5.00
406,005
18.33M
US$ 6.740M
US$ 0.47
-0.01 -2.25
28,339
14.39M
US$ 6.690M
US$ 0.41
0.006 1.50
12,450
15.17M
US$ 6.160M
US$ 3.34
-0.09 -2.62
11,505
1.80M
US$ 6.010M
US$ 0.03
-0.0023 -7.93
5,236
224.63M
US$ 5.990M
US$ 0.07
-0.01 -15.77
303
88.23M
US$ 5.790M
US$ 3.53
-0.02 -0.59
6,299
1.62M
US$ 5.720M
US$ 0.06
-0.0088 -13.54
628,700
97.06M
US$ 5.460M
US$ 0.11
0.00 0.00
0
47.66M
US$ 5.220M
US$ 0.15
-0.03 -16.67
11,425
34.19M
US$ 5.130M
US$ 0.08
0.00 0.00
0
66.67M
US$ 5.030M
US$ 0.04
-0.0001 -0.24
30,260
111.14M
US$ 4.580M
US$ 0.34
0.0035 1.04
153,089
12.98M
US$ 4.390M
US$ 1.14
-0.03 -2.56
67,649
3.15M
US$ 3.590M
US$ 0.03
-0.0027 -9.64
88,490
121.27M
US$ 3.070M
US$ 1.15
-0.14 -10.85
122,767
2.47M
US$ 2.840M
US$ 0.02
0.00 0.00
0
132.63M
US$ 2.650M
US$ 0.05
0.00 0.00
0
51.46M
US$ 2.620M
US$ 0.66
-0.04 -5.80
182,405
3.01M
US$ 1.990M
US$ 0.005
0.00 0.00
0
365.36M
US$ 1.830M
US$ 0.04
0.00 0.00
0
45.93M
US$ 1.670M
US$ 0.02
0.00 0.00
1,000
79.41M
US$ 1.420M
US$ 0.01
0.00 0.00
0
88.94M
US$ 1.300M
US$ 0.63
-0.07 -10.56
2.51M
2.02M
US$ 1.270M
US$ 0.00975
-0.0017 -14.91
11,050
97.28M
US$ 948K
US$ 0.008
-0.0031 -27.93
8,330
103.35M
US$ 827K
US$ 0.20
0.0011 0.54
24,820
2.39M
US$ 489K
US$ 0.0035
0.00 0.00
0
120.69M
US$ 422K
US$ 0.007
-0.0025 -26.32
20,741
36.50M
US$ 256K
US$ 1.35
0.00 0.00
0
-
US$ -

BioTech Stock News


StageZero Life Sciences, Ltd Announces Q4 2022 and Year End Financial Results and Operational Update

Toronto, Ontario--(Newsfile Corp. - March 31, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company"), a vertically-integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced its fourth quarter and full year financial results for the... Read more


Healthy Extracts Reports Record Fiscal Year 2022 Financial Results

LAS VEGAS, March 31, 2023 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading developer and distributor of plant-based nutraceutical products for heart and brain health, reported results for the year ended December 31, 2022. All comparisons are to the year-ago period unless otherwise noted. 2022 Financial Highlights Net revenue totaled a record $2.3 million, up 34%, due to product... Read more


ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Update

YONKERS, N.Y., March 31, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces business updates and financial results for the... Read more


NightHawk Biosciences Provides 2022 Year End Business Update

DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates for the year ended December 31, 2022. Jeff Wolf, Chief Executive Officer of NightHawk, commented, “We are making progress... Read more


Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K

SAN DIEGO, CA, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY) (“Sigyn Therapeutics” or the “Company”), a development-stage company that creates blood purification technologies to address unmet needs in global health, announced today the filing of its Form 10-K annual report with the United States Securities and Exchange Commission ("SEC") for... Read more


bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results

Conference Call Scheduled for April 3, 2023, at 9:00 a.m. Eastern Time SAN ANTONIO / Mar 31, 2023 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three and 12 months ended December 31, 2022. Financial Hig... Read more


Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results

12-month interim data from the ongoing 2-year, Phase 2 Stargardt disease (STGD1) study continues to show halting or slowing of lesion growth; 18-month efficacy and safety update expected during the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on April 25 42 subjects have been enrolled for the pivotal Phase 3 “DRAGON” trial evaluating oral tinlarebant in adolescent... Read more


TransCode Therapeutics Reports 2022 Results; Provides Business Update

BOSTON, March 31, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial results for 2022 and recent business progress. “Despite the continued turbulence in the biotech sector, 2022 was extremely productive and, we believe, successful for TransCode. The year was highlighted by... Read more


Check-Cap Reports Fourth Quarter and Full Year 2022 Financial Results

ISFIYA, Israel, March 31, 2023 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced financial results for the... Read more


Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells

LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that an editorial written by Maria Sjöstrand and Michel Sadelain of Memorial Sloan Kettering Cancer Center was published 2023 in Haematologica highlighting NXC-201 in the context of the current U.S. Food And Drug... Read more


SeaStar Medical Reports 2022 Financial Results and Provides a Business Update

DENVER, March 30, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides a business update and reports financial results for the year ended December 31, 2022. “We are focusing on executing near-term... Read more


Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results

Corporate Update Call to be Held Tuesday, April 11, 2023  SAN DIEGO, CA / ACCESSWIRE / March 30, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and full year of 2022. Dr. Lynn Kirkpatrick, Chief Executive... Read more


Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update

NORCROSS, Ga., March 30, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2022. These results are included in the Company's Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange... Read more


Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

Dosed the first patient in VIRAGE, a Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma  Dosed the first patient in the investigator sponsored Phase 1 clinical trial of VCN-01 for patients with brain tumors  Presented positive safety and pharmacokinetic data from the ongoing Phase 1b/2a clinical trial of... Read more


Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

Advanced platform achieving multiple industry breakthroughs including creation and validation of de novo antibodies using zero-shot generative AI 10 new Active Programs in 2022, exceeding full-year guidance VANCOUVER, Wash. and NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the generative AI drug creation company, today reported financial and operating results... Read more


Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022

Initiated registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational study First subject dosed in Phase 1/2a clinical trial for LB101, a PD-L1xCD47 LockBody® to treat solid tumors; Preclinical data from second LockBody program targeting PD-L1xCD3 expected in 2023 Nominated ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist,... Read more


IMUNON Reports 2022 Financial Results and Provides Business Update

Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the year ended December 31, 2022, and provided an update on its clinical development programs with... Read more


Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

Biora initiating preclinical testing with pharma collaborator’s molecule following recent data exceeding the company’s target bioavailability levels for systemic therapeutics platform No adverse events indicated in 14-day tox study for targeted therapeutics program Announcing new brand names for Biora’s therapeutics platforms: the NaviCap™ targeted oral delivery platform and the BioJet™... Read more


Fresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Positive topline results from single and multiple ascending dose parts of the Phase 1 study of FRTX-02 support its continued development as a potential first-in-class, once-daily oral treatment for atopic dermatitis and/or other autoimmune diseases Continuing to evaluate strategic options to further develop FRTX-02 and maximize shareholder value Raised aggregate net proceeds of $6.6 million... Read more


Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

BASKING RIDGE, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the three and twelve months ended December 31, 2022. “Last... Read more


IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

All Cohort 1 leukemia patients have maintained durable morphological complete responses (CR) beyond 18 months and up to 2.7 years in an ongoing Phase 1 trial of INB-100 as of December 9, 2022; Updated clinical data to be reported at the EBMT Annual Meeting in April 2023 INB-200 continued to show durable and favorable responses, with ongoing patients extending beyond 1.5 years and 1.2 years progression... Read more


NervGen Pharma Reports 2022 Year End Results and Provides Operational Update Including Plans to Initiate Phase 1b/2a Clinical Trial of Proprietary NVG-291 in Q3 2023

Equity proceeds of CA$22M+ raised during 2022 fiscal year Phase 1 clinical trial dosing of proprietary compound, NVG-291, is complete and data analysis is ongoing Phase 1b/2a clinical trial of NVG-291 to include individuals with chronic and subacute spinal cord injuries Vancouver, British Columbia--(Newsfile Corp. - March 30, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen"... Read more


Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

FDA granted Fast Track Designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine candidate  Completed dosing in ongoing Phase 1 study of IVX-A12; topline interim results expected in 2Q 2023  Initiation of IVX-A12 Phase 2 trial expected in 2H 2023  Cash and cash equivalents, restricted cash, and short-term investments of... Read more


Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights

Fortress expects to file a total of three new drug applications in 2023 Record consolidated net revenue of $75.7 million for full-year 2022 FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of January 3, 2024 Rolling NDA submission for CUTX-101 for the treatment of Menkes... Read more


Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility

Facility to enable access to manufactured mRNA vaccines for Kenya and the African continent, providing health security and building upon Moderna's global public health commitments The facility will be capable of producing up to 500 million doses each year CAMBRIDGE, MA & NAIROBI, KENYA / ACCESSWIRE / March 30, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger... Read more


BriaCell Therapeutics Announces Intention to Spin-Out Certain Pre-Clinical Assets into a Newly Created “SpinCo” Entity whereby Shareholders to Receive One New Share of “SpinCo” in Addition to Each...

SpinCo Assets (SpinCo) includes Bria-TILsRx™, and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer. SpinCo’s goal is to potentially accelerate the development of its assets, and to create value. PHILADELPHIA and VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or... Read more


Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma

CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today announced a clinical supply agreement with Roche to evaluate OTX-2002, its lead candidate in development for the treatment of MYC-driven hepatocellular carcinoma... Read more


ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas

Agreement Focuses on in silico and de novo Discovery and Development of Antibodies Against Tumor Microenvironment Targets. Program will Leverage BioStrand’s (a Talem Affiliate) LENSai® Integrated Intelligence Technology®, Built Upon the Proprietary HYFT Index®. VICTORIA, British Columbia / Mar 30, 2023 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or... Read more


RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy

RenovoGem™ Patients had Greater than 65% Reduction in Side Effects, which can Include Nausea, Fatigue, and Reduced White Blood Cells During Pancreatic Cancer Treatment These Data and Additional Secondary Endpoint Analyses to be Presented at American Association for Cancer Research (AACR) Annual Meeting on April 17, 2023 LOS ALTOS, Calif. / Mar 30, 2023 / Business Wire / RenovoRx, Inc. (“... Read more


Kiora Pharmaceuticals Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 Meeting

Encinitas, California--(Newsfile Corp. - March 30, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced its late-breaking abstract detailing functional Magnetic Resonance Imaging (fMRI) results from the ABACUS Phase 1b study of KIO-301 in patients with retinitis pigmentosa was accepted for presentation on May 1, 2023, at The American Society of Neuroradiology 2023... Read more

COPYRIGHT ©2022 GREEN STOCK NEWS